



SVF Vaccines partners with Touchlight to accelerate SVF-001 toward clinical development

Stockholm, Sweden, 9 April 2026. SVF Vaccines AB (“SVF Vaccines” or the “Company”), a Swedish biotechnology company developing vaccines and immunotherapies for serious infectious diseases, today announced a collaboration with Touchlight, a biotechnology company specialising in cell-free DNA manufacturing, to accelerate the continued advancement of the Company’s lead hepatitis B/D immunotherapy program, SVF-001, toward clinical development.

Under the collaboration, SVF Vaccines and Touchlight are working together to support the use of Touchlight’s proprietary doggybone DNA™ (dbDNA™) platform, a cell-free DNA technology designed to enable rapid, scalable and high-purity DNA manufacturing. The collaboration is expected to support an efficient path forward as SVF Vaccines advances SVF-001 and prepares the program for the next stage of development.

SVF-001 is SVF Vaccines’ lead immunotherapy candidate for hepatitis B and D and represents a novel approach designed to induce both neutralising antibody responses and T-cell responses against key viral targets. The collaboration with Touchlight brings complementary scientific and technical expertise to the program, with a shared focus on enabling high-quality DNA production to support future development activities.

“This is an important collaboration for SVF Vaccines at a highly relevant stage of our development,” says Raheleh Nassaji, CEO of SVF Vaccines AB. “Access to Touchlight’s fast and flexible DNA technology gives us an efficient and scalable path forward as we continue advancing SVF-001 toward clinical development. We believe this collaboration strengthens our execution capabilities and supports our ambition to bring our hepatitis B and D program into the clinic as soon as possible.”

Touchlight’s dbDNA™ platform is a cell-free alternative to plasmid DNA manufacturing and, according to the company, is designed to reduce timelines, improve scalability and support genetic medicine programs across multiple applications. For SVF Vaccines, the collaboration represents a strategically important step in aligning the program with manufacturing solutions intended for efficient clinical translation.



For further information, please contact:

Raheleh Nassaji, Chief Executive Officer, SVF Vaccines AB
Phone: +46 (0) 76 495 12 85, e-mail: raheleh.nassaji@svfvaccines.com

John Öhd, Chairman of the Board, SVF Vaccines AB
Phone: +46 (0) 70 766 80 97, e-mail: john.ohd@karolinskadevelopment.com

About Touchlight

Touchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers with an FDA Drug Master File accepted in 2022 followed in 2025 with the world's first cell-free DNA GMP license, Touchlight's enzymatic DNA technology is on the cutting edge of viral vectors, mRNA, non-viral gene therapy, DNA vaccine, and gene editing innovation. With multiple client products already in the clinic, Touchlight's evidence-based, synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. The company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, Touchlight's team is inspired by breakthroughs in genetic medicine, recognising the urgent need for innovative DNA production techniques to support the future of genetic therapies.

About SVF Vaccines

SVF Vaccines is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies targeting serious viral infections. The company's pipeline is built on proprietary antigen design strategies that aim to induce both potent neutralising antibody responses and durable T-cell immunity. By combining innovative immunogen design with strategic partnerships in manufacturing and development, SVF Vaccines is advancing a portfolio of programs with the potential to address significant unmet medical needs. Their mission is to develop vaccines and immunotherapies in order to prevent and treat life-threatening diseases.